NantWorks controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile1 entries
2015
Cynviloq transaction and alleged failure to advance development
NantPharma acquired Cynviloq from Sorrento Therapeutics. Later allegations claimed that regulatory milestones and patent deadlines were allowed to lapse, effectively preventing the medicine from competing with another product connected to Soon-Shiong's interests. The allegations were reported as a controversy involving related entities; the supplied material does not establish a final adjudication against NantWorks itself.